José Javier Serer Ripoll

Clinical Oncologist

[José Javier Serer Ripoll @JJSererRipoll]

Excelente encuentro federal de @SUMAargentina en San Juan @fwaisberg1 @PabloMando

[SUMA 🇦🇷 @SUMAargentina]

Hoy tenemos el honor de participar en un nuevo Encuentro Federal de @SUMAargentina en San Juan 🇦🇷 @JJSererRipoll @fwaisberg1

[José Javier Serer Ripoll @JJSererRipoll]

@SirChandlerBlog Bienvenido a San Juan Sir! No dejes de probar la punta espalda…

[Yüksel Ürün @DrYukselUrun]

ME: doing my best to stay updated in oncology!

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

Terrific debate featuring Drs Virginia Borges and Martine Piccart on the role of anthracyclines in early breast cancer. This summary from Dr Piccart captures much of the final recommendation

[Hope Rugo @hoperugo]

Big news: approval in the altered population only. Great to have this new option! ⁦@OncoAlert⁩ FDA approves capivasertib with fulvestrant for breast cancer | FDA https://t.co/J6msOP5x84

[José Javier Serer Ripoll @JJSererRipoll]

Gran discusión de cáncer de mama oligometastásico con colegas y amigos. Gracias @aaoncoclinica por la invitación
#congresoAAOC23
#equipomultidisciplinario

[José Javier Serer Ripoll @JJSererRipoll]

https://t.co/NsqlsUwXuE

[Ryan Huey, MD, MS @ryanhuey]

Oof. 😓 Burnout among oncologists has increased from 34% to 59% over the past 10 years. 22% likely to reduce clinical hours in the next year (up from 16%). #ASCOQLTY23

[Sociedad Argentina de Cardiología @SAC_54]

🔵Comunicado Intersocietario: Sociedades de Cardiología reclaman por falta
de insumos indispensables

[José Javier Serer Ripoll @JJSererRipoll]

@gladiadormerval Maximus Decimus Meridius

[José Javier Serer Ripoll @JJSererRipoll]

@huntmart1984 Se les recuerda

[Yakup Ergün @dr_yakupergun]

Assessment of use and impact of chemotherapy in T1aN0 TNBC

1,739 pts (SEER Database)

📌Adjuvant chemotherapy is not associated with benefit on OS (HR, 0.63; 95% CI, 0.35-1.13) or BCSS (HR, 0.95; 95% CI, 0.37-2.43)

(CI too wide!)

@CBCjournal
https://t.co/wZDsw1U3QK

[Carlo Palmieri @cancermedic]

D-TORCH Study: Topical 1% diclofenac ⬇️ incidence of grade 2+ & all grade hand-foot syndrome. #ASCO23 so devilishly simple, easy to implement & a treatment that doesn’t bust the 🐷bank. What’s not to like?

[Paolo Tarantino @PTarantinoMD]

The KM curve everyone’s been waiting for. Adjuvant ribociclib for 3 years significantly improved iDFS in patients with stage II-III HR+ BC, with 25% reduction in the risk of recurrence & a 3-year iDFS delta of 3.3%. #ASCO23

[Pablo Mando @PabloMando]

Finishing an amazing short stay in @hospitalclinic with Dra. Maria Vidal! Thank you Maria! I even got to know @prat_aleix lab at @idibaps Now headed to Berlin to present a poster! #ESMOBreast2023 #ESMOYOC @myESMO @fwaisberg1 @JJSererRipoll @CMicheri

[Pablo Mando @PabloMando]

📣📣📣Amazing results of the addition of Dostarlimab to chemotherapy in first line endometrial cancer. 🔥for dMMR/MSI-H @myESMO #ESMOVirtualPlenary

https://t.co/KkLqtSzDcy

[José Javier Serer Ripoll @JJSererRipoll]

@PabloMando @myESMO @SergioRiveroMD @fwaisberg1 Great team!

[Pablo Mando @PabloMando]

Berlin, here we go!!! #ESMOBreast2023 @myESMO First collaborative work from YOGA-B. Awesome team work!!! @SergioRiveroMD @fwaisberg1 @JJSererRipoll

[José Javier Serer Ripoll @JJSererRipoll]

@kedesirteee Venite